To members of the pulmonary fibrosis community,

The Pulmonary Fibrosis Foundation has been closely monitoring the impact of coronavirus (COVID-19) and its spread throughout the United States. The number of patients affected by COVID-19 is increasing and our understanding of the effects of the virus is expanding. Based on experiences throughout the world and more recently in the U.S., people who have chronic medical issues may be at higher risk for serious illness from COVID-19, including those with pulmonary fibrosis. Public health officials recommend patients in the higher risk category should reduce the risk of being exposed to COVID-19.

To limit or prevent the spread of COVID-19, several recommendations have been suggested by the Centers for Disease Control (CDC) and include:

1. Wash your hands often and with soap and water for at least 20 seconds, especially after going to the bathroom, before eating, and after blowing your nose, coughing, or sneezing.
   a. If soap and water are not readily available, use an alcohol-based hand sanitizer with at least 60% alcohol.
      i. CDC’s Handwashing Information
2. Avoid close contact with people who are sick, distancing yourself by at least six feet.
3. Avoid touching your eyes, nose and mouth.
4. Stay at home if you are sick.
5. Cover your cough and sneeze with a tissue, then throw the tissue in the trash.
6. **Clean and disinfect frequently touched objects and surfaces using a regular household cleaning spray or wipe.**

7. **Wear a mask that fully covers your nose and mouth whenever you are with people who don’t live with you. Layering a cloth mask over a disposable mask, knotting and tucking ear loops, or using a mask filter may improve fit and filtration. This is in addition to adhering to distancing measures of staying at least six feet apart from others. N95 respirators should be reserved for health care professionals. Follow the CDC’s Instructions on How to Wear a Face Covering.**

8. **The CDC provides guidance and a video on how to make your own face covering.**

9. **Avoid non-essential travel.**
   a. Stay at home as much as possible.
   b. Make sure your medications and supplies are adequate for a prolonged period of time.
   c. Avoid crowds, including in places such as entertainment venues, sporting events, and places of worship.

**Common Questions**

**What are the symptoms of COVID-19 infection?**

While symptoms may vary from few or no symptoms to severe breathing difficulty, more common symptoms include:

- Fever (Temperature over 100.4°F)
- Muscle pain or body aches
- Worsening cough
- Increased shortness of breath
- Chills
- Repeated shaking with chills
- Headache
- Sore throat
- New loss of taste or smell
- Congestion or runny nose
- Nausea or vomiting
- Diarrhea
**What should I do if I think I have been infected with COVID-19?**

If you get sick, stay home and call your pulmonologist. If he/she is not available, contact your primary care physician. Let your doctor know about your symptoms and that you may have COVID-19. Get medical attention immediately if you have:

- More difficulty breathing or shortness of breath
- Persistent pain or pressure in the chest
- New confusion or inability to arouse
- Bluish lips or face
- Increased oxygen requirement

**How does COVID-19 impact patients with interstitial lung disease (ILD)?**

Emerging studies indicate that ILD patients who are hospitalized with COVID-19 have worse outcomes than matched COVID-19 patients without ILD. (Source: [https://www.atsjournals.org/doi/pdf/10.1164/rccm.202007-2794OC](https://www.atsjournals.org/doi/pdf/10.1164/rccm.202007-2794OC)). It is important to note that more research is needed to gain a better understanding of the impact of COVID-19 on patients with ILD.

**Should I get vaccinated for COVID-19?**

In accordance with [Recommendations issued by the Centers for Disease Control and Prevention](https://www.cdc.gov/vaccines/priority-list/adults/adult-immunization-schedule.html), the PFF strongly encourages vaccination for COVID-19, as the benefits far outweigh the risks. The authorized vaccines have been demonstrated to be safe and extremely effective in preventing COVID-19 and/or limiting the development of severe COVID-19. Following vaccination, individuals should continue to adhere to safe practices, including the use of face coverings, hand washing, and physical distancing until the prevalence of the SARS-CoV-2 virus in the community is significantly reduced. To ensure that you are not part of the limited population for whom vaccination is not recommended at this time, we encourage you to reach out to your primary care physician and pulmonologist for more information.

COVID-19 variants have recently emerged around the world and in the U.S., and some of these strains of the virus are known to spread more easily. This may mean that for those who are exposed to these variants, immunity from a previous COVID-19 infection or from a COVID-19 vaccination may not be as effective at preventing infection, though
more research needs to be done to fully understand the impact of the new COVID-19 variants.

People who are eligible to receive the COVID-19 vaccine should proceed with vaccination, as the currently authorized vaccines are highly effective in reducing the severity and spread of disease. Strategies that are known to reduce the spread of infection, such as wearing a mask, social distancing, and frequent hand washing, remain crucial in limiting the spread of COVID-19, especially as new variants of the disease are discovered.

For those who have been fully vaccinated for more than two weeks, the CDC has provided interim recommendations on visiting with other fully vaccinated people. It is important to continue to adhere to preventive measures when in public and with unvaccinated individuals.

**Is it safe to travel for routine clinic visits?**

The risk of traveling for clinic appointments is dependent upon the spread of COVID-19 in your area and the clinic in which you are seen. If you have concerns about traveling for a clinic appointment, you should discuss your specific situation and risks with your care center. There have been expansions in telemedicine during the COVID-19 pandemic, so you should talk to your doctor to determine if telehealth visits are an option. For the most up-to-date information on COVID-19, we recommend visiting the [CDC Coronavirus Disease 2019 webpage](https://www.cdc.gov/coronavirus). If you have a fever or worsened cough and shortness of breath, you should alert your physician before arriving to a clinic/hospital for an appointment.

**Should I continue traveling to my pulmonary rehabilitation appointments?**

To avoid person-to-person transmission of COVID-19, patients should avoid crowds and stay at home as much as possible, especially if they are at higher risk for serious illness like those with PD. We recommend discussing the risks of participating in pulmonary rehab sessions with your pulmonary rehab team and physician. Home exercise programs may be developed in discussion with your pulmonary rehab center and physician during the COVID-19 pandemic. Several online resources are available to assist patients with exercise training. Discussing the use of these tools with your physician is recommended prior to initiating a home program.

[Pulmonary Rehab/ Daily Fitness & Exercise](https://www.pulmonaryfibrosis.org)
[Pulmonary Rehabilitation for Chronic Lung Conditions](https://www.pulmonaryfibrosis.org)
[Pulmonary Rehab Home Program](https://www.pulmonaryfibrosis.org)
Is it safe to have a pulmonary function test (PFT) or spirometry during the COVID-19 pandemic?

Patients have expressed concerns about whether they can become infected with COVID-19 by doing PFTs and spirometry testing. First and foremost, if you have a fever or increased cough and shortness of breath, you should alert your physician before arriving to a clinic/hospital for an appointment and/or testing. If you have concerns about routine testing, you should discuss any questions with the testing center and your physician. Some centers are canceling non-urgent, routine testing during the COVID-19 pandemic and opting to reschedule at a later date.

How can I prevent the virus from entering my portable oxygen concentrator (POC)?

The filters in POCs are not designed to filter viruses. Oxygen equipment should be cleaned, and filters replaced as specified by the manufacturer for routine maintenance. It is now more important than ever to clean and disinfect frequently touched objects, including POCs. Also, wash your hands frequently and adhere to social distancing guidelines.

Should I wear a mask with an exhalation valve or vent?

It is important to wear a face covering when in public to help reduce the spread of COVID-19. Wearing a face covering can prevent the wearer’s respiratory droplets from reaching other people. In addition, face coverings offer some protection to the wearer, but they are not a substitute for physical distancing. Face coverings should be worn in addition to maintaining a six-foot distance from others.

Note that masks with one-way valves or vents allowing the wearer to exhale through the valve can result in the wearer’s respiratory droplets reaching others. This type of mask is not recommended by the CDC, as it does not prevent the person wearing the mask from transmitting COVID-19 to others.

I am enrolled in a clinical trial. Should I continue going to study appointments?

The FDA has issued new guidelines for clinical trial investigators in response to the COVID-19 outbreak. In addition, the FDA has developed information for patients who are enrolled in a clinical trial. If you are enrolled in a current trial, contact your trial center for information about any changes in visits. In order to avoid the risk of infection, appointments may need to be rescheduled. Ensuring your safety and limiting your potential exposure to the virus is a major concern.
How can I get involved in a clinical trial related to COVID-19?

The PFF Clinical Trial Finder has been updated to include clinical trials related to COVID-19, in addition to PF-related clinical trials. Typing “COVID-19” in the “Keyword” filter of the PFF Clinical Trial Finder will show studies related to COVID-19. If you are interested in participating in any of these trials, you should contact the listed site coordinator for the trial via phone or email. You can also find clinical trials investigating COVID-19 on the website of the National Institutes of Health at https://clinicaltrials.gov.

I am a lung transplant recipient. How can I protect myself from infection?

Lung transplant recipients should use an abundance of caution. Stay near your home and with those you live until the outbreak subsides. If you take a walk around the block, be sure to practice social distancing (distance yourself from other people by six feet). Ask family members or neighbors for help with getting groceries and essentials. Follow the advice of your transplant team with regard to the use of a face covering. The CDC now recommends that everyone wear cloth face coverings in public.

I am on the lung transplant waiting list. What should I do?

Patients on the waiting list for a lung transplant should maintain contact with their transplant center. According to the American Society of Transplantation, the risk of acquiring COVID-19 from an organ donor is low. However, transplant surgery may be delayed due to the threat of exposure in the hospital and the current strain on medical personnel and resources.

Can COVID-19 lead to pulmonary fibrosis?

Some news reports connecting PF with COVID-19 have been misleading. COVID-19 patients may develop acute respiratory distress syndrome (ARDS) which results in respiratory failure and the need for mechanical ventilation. In an attempt to heal from these overwhelming injuries, patients can lead to post-ARDS fibroproliferation or “fibrosis”. This could compound the injury which already exists in patients with PF and can be life threatening. We urge you to take the recommendations for avoiding COVID-19 infection seriously.

Will my anti-fibrotic treatment help prevent me from contracting COVID-19? Is the medication being used as a treatment for COVID-19?
While a tremendous amount of research and clinical trials for coronavirus treatments are underway, there is currently no clinical evidence that anti-fibrotic therapies approved to treat forms of pulmonary fibrosis are safe or effective in preventing and/or treating patients infected with coronavirus. Several studies are investigating the use of anti-fibrotics approved for various forms of PF to treat patients who have developed lung fibrosis as a result of COVID-19. If you’re interested in learning more, the PFF’s Drug Development Pipeline now includes therapeutic agents and devices that are in clinical trials to treat COVID-19. You can also visit clinicaltrials.gov for a complete list of COVID-19 studies worldwide.

Is hydroxychloroquine an effective treatment for COVID-19?

The Food and Drug Administration (FDA) has revoked the emergency use of hydroxychloroquine for the treatment of COVID-19. The known and potential benefits of chloroquine and hydroxychloroquine no longer outweigh the known and potential risks of use. The National Institutes of Health recommends against all use of chloroquine or hydroxychloroquine for the treatment of COVID-19, except in a clinical trial. In addition, the World Health Organization halted research on hydroxychloroquine as a treatment for COVID-19 after studies showed that the drug has no impact on the virus.

Is remdesivir an approved treatment for COVID-19?

The FDA has approved remdesivir, an antiviral drug, as a treatment for patients who are hospitalized and severely ill with COVID-19. The approval of remdesivir was supported by data from clinical trials that included patients hospitalized with mild-to-severe COVID-19.

When will it be safe to go out again?

This is an important question that cannot be generalized to any one country, state, or region. Given the risks of COVID-19 to the PF community, a personal plan should be discussed with your pulmonologist before resuming public interactions. Individuals living with PF should continue to practice social distancing and minimize exposure to social settings where distancing may not be practical. Infection may be spread through airborne transmission of smaller droplets and particles that can remain suspended in the air over greater distances or over longer times. Therefore, be sure to continue to use everyday preventive actions such as washing your hands, covering coughs and sneezes, avoiding touching your face, disinfecting frequently used items and surfaces, and wearing face coverings to reduce the spread of infection.
For more information about deciding to go out, see the CDC’s considerations and tips for reducing your risk.

**What is known about immunity to COVID-19 in those who were previously infected?**

The latest research on COVID-19 indicates that people can continue to test positive for up to three months after diagnosis and not be infectious to others. This does not imply a person is immune to reinfection with SARS-CoV-2, the virus that causes COVID-19, in the three months following infection. Rather, the data suggests that retesting someone in the three months following initial infection is not necessary unless that person is exhibiting the symptoms of COVID-19 and the symptoms cannot be associated with another illness. More study is needed to better understand whether COVID-19 patients are immune to reinfection, and if so, how long that immunity may last. Those who have recovered from COVID-19 should continue to follow CDC recommendations for avoiding infection, including practicing social distancing, wearing a face covering, frequent handwashing, and avoiding non-essential errands, gatherings, and travel.

The Pulmonary Fibrosis Foundation is monitoring the dynamic situation with COVID-19 and will address additional questions and future plans for PFF events and programs depending on the evolving situation throughout the United States.